Q4 2007 Net Revenues - $28.9 million vs. $19.9 million in Q4 2006 - a 45%
Q4 2007 Diluted Net Income per Share - $0.10 vs. $0.04 in Q4 2006
Q4 2007 New Bookings Increase to $39.2 million
PHILADELPHIA, Feb. 26 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized ECG, eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device and related industries, announced today results for the fourth quarter of 2007 and the twelve-month period ended December 31, 2007.
On November 28, 2007, the Company acquired Covance Cardiac Safety
Services, Inc. (CCSS) and entered into a ten-year exclusive marketing
agreement with Covance, Inc. Because there is only one month of impact on
its results for 2007, the Company reported key statistics with and without
the CCSS acquisition. Unless otherwise noted, all growth numbers refer to
changes from the same period a year ago.
Highlights of the fourth quarter and the year were:
-- Record quarterly net revenue of $28.9 million for the fourth quarter of
2007 (including $1.5 million from the CCSS transaction) a 45.1%
increase from the prior year's quarter. Net revenues for the full year
2007 were $98.7 million.
-- Gross margin percentage increased to 52.6% which would have been higher
by 2.5% had we excluded the CCSS acquisition (or 55.1%); for the full
year 2007, the gross margin percentage was 50.7%.
-- Pre-tax margin percentage increased to 27.8% which would have been
higher by 3.3% had we excluded the CCSS acquisition (or 31.1%); for the
full year 2007, the pre-tax margin percentage was 24.8%.
-- Diluted net income per share increased to $0.10, which would have been
$0.01 higher had we excluded the CCSS acquisition (or $0.11); for the
full year 2007, diluted net income per share was $0.29.
-- New bookings increased to $39.2 million, an increase of 42.5%; for 2007
new bookings were a record $138.6 million.
-- Backlog increased to $140.2 million as of December 31, 2007 (including
the CCSS acquisition), an increase of 45.4% from the prior year.
The Company reported net income of $5.2 million for the fourth quarter of 2007, a 129.9% increase from $2.2 million in the fourth quarter of 2006. Diluted net income per share was $0.10 in the fourth quarter of 2007 (which was negatively affected by the CCSS transaction by $0.01), compared to $0.04 in the fourth quarter of 2006.
"We feel that the fourth quarter was a very successful one -- we recorded the highest level of net revenues in eRT's history, increased net income by 129.9%, recorded a near record level of new bookings, processed the highest number of ECG transactions in eRT's history and completed the acquisition of CCSS," said Dr. Michael McKelvey, President and CEO of eRT. "For the year, we grew net revenues by 14.3% and the bottom line by 83.5%, demonstrating the leverage of our operating model. We also recorded the highest level of new bookings in eRT's history. The CCSS integration is moving along as planned and will be an important factor in our long-term growth."
For the full year ended December 31, 2007, the Company reported net revenues of $98.7 million compared to $86.4 million for the full year ended December 31, 2006, a 14.3% increase. The Company's gross margin percentage for 2007 was 50.7% compared to 48.4% for 2006. Pre-tax income percentage for 2007 was 24.8% compared to 15.3% for 2006. The Company reported net income of $15.3 million, or $0.29 per diluted share, for 2007 compared to net income of $8.3 million, or $0.16 per diluted share, for 2006, an 83.5% increase. The Company's effective tax rate was 37.6% for 2007 compared to 37.1% for 2006.
Cash flow from operations for 2007 was $36.0 million, up from $16.3 million in 2006. After completing the CCSS transaction of $35.8 million, eRT ended the year with $46.9 million in cash, cash equivalents and investments.
Commenting on the year as a whole, Dr. McKelvey said "Our success in 2007 gives us a strong basis for growth in 2008 and beyond. We enter 2008 with a healthy backlog, a good trajectory of revenue growth, enhanced scale and increased market share from our recent acquisition, a strong pipeline of bookings opportunities and a state-of-the-art new workflow system (EXPeRT(R) 2) that provides us with a scalable platform for operational excellence. The clinical trials industry continues to focus on the importance of cardiac safety and running Thorough QTc trials. In addition, we also invested in our eClinical line of business and launched a new line of business -- electronic patient reported outcomes (ePRO)." As for 2008, Dr. Michael McKelvey concluded: "The strong momentum that we developed throughout 2007, along with a healthy overall business environment for cardiac safety and the need for technology-based solutions for clinical trials, gives us confidence that we will have a successful 2008."
The Company issued guidance for the first quarter of 2008. eRT anticipates net revenues of between $31.0 million and $33.0 million and net income per diluted share of $0.08 to $0.10 for the first quarter ending March 31, 2008. For the full year ending December 31, 2008, management anticipates net revenues of between $130 million and $137 million. Management anticipates earnings per diluted share of between $0.42 and $0.46 for the full year ending December 31, 2008. This guidance includes the costs associated with the closing of the Reno facility and other integration costs of CCSS. Costs associated with this will be more heavily skewed to the first three quarters of the year. Revenue and gross margin for the first three quarters will also include a higher percentage of lower margin backlog revenue then in the later part of the year.
Dr. McKelvey and Richard Baron, the Company's Chief Financial Officer, will hold a conference call to discuss these results. The conference call will take place at 5:00 p.m. EST on February 26, 2008. For the conference call interested participants should dial 866-578-5771 when calling within the United States or 617-213-8055 when calling internationally along with the pass code 91743845. There will be a playback available through 11:59 p.m. (Eastern) on March 4, 2008. To listen to the playback, please call 800-286-8010 when calling within the United States or 617-801-6888 when calling internationally. Please use pass code 46120621 for the replay.
This call is being webcast by Thomson Financial and can be accessed at eRT's web site at http://www.eRT.com. The webcast may also be accessed at http://phx.corporate-ir.net/playerlink.zhtml?c=119164&s=wm&e=1764127. The webcast can be accessed until February 26, 2009 on either site.
About eResearchTechnology, Inc.
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements, including, but not limited to, 2008 financial
guidance, involve a number of risks and uncertainties such as the Company's
ability to obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and duration of
projects, and internal issues at the sponsoring client, integration of
acquisitions, competitive factors, technological development, and market
demand. As a result, actual results may differ materially from any
financial outlooks stated herein. Further information on potential factors
that could affect the Company's financial results can be found in the
Company's Reports on Form 10-K and 10-Q filed with the Securities and
Exchange Commission. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise.
eResearchTechnology, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share amounts)
Three Months Ended December 31, The Year Ended December 31,
2006 2007 2006 2007
(unaudited) (unaudited) (unaudited)
Licenses $681 $687 $3,017 $2,700
Services 13,269 21,565 55,309 69,547
Site support 5,975 6,657 28,042 26,451
Total net revenues 19,925 28,909 86,368 98,698
Costs of revenues:
Cost of licenses 58 105 286 304
Cost of services 6,301 8,932 25,431 30,522
Cost of site support 4,329 4,665 18,821 17,808
Total costs of revenues 10,688 13,702 44,538 48,634
Gross margin 9,237 15,207 41,830 50,064
Selling and marketing 2,364 3,143 11,051 11,222
administrative 2,910 3,343 14,668 12,258
development 818 1,178 4,146 4,333
expenses 6,092 7,664 29,865 27,813
Operating income 3,145 7,543 11,965 22,251
Other income, net 183 503 1,250 2,206
Income before income
taxes 3,328 8,046 13,215 24,457
Income tax provision 1,084 2,887 4,905 9,205
Net income $2,244 $5,159 $8,310 $15,252
Basic net income per
share $0.04 $0.10 $0.17 $0.30
Diluted net income per
share $0.04 $0.10 $0.16 $0.29
Shares used to
net income per share 49,988 50,618 49,474 50,476
Shares used to
net income per share 51,364 51,929 51,485 51,743
eResearchTechnology, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
December 31, 2006 December 31, 2007
Cash and cash equivalents $15,497 $38,082
Short-term investments 41,416 8,797
Accounts receivable, net 17,866 26,718
Prepaid income taxes 2,819 743
Prepaid expenses and other 2,761 3,087
Deferred income taxes 912 901
Total current assets 81,271 78,328
Property and equipment, net 31,129 33,347
Goodwill 1,212 30,908
Long-term investments 928 -
Intangible assts - 3,849
Deferred income taxes - 1,011
Other assets 524 253
Total assets $115,064 $147,696
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable $4,360 $3,505
Accrued expenses 3,445 12,103
Income taxes payable 781 2,352
Current portion of capital lease obligations 40 1,097
Deferred revenues 11,325 13,905
Total current liabilities 19,951 32,962
Capital lease obligations, excluding current
portion - 48
Deferred income taxes 1,491 -
Other liabilities - 1,174
Total liabilities 21,442 34,184
Preferred stock-$10.00 par value, 500,000
shares authorized, none issued and outstanding - -
Common stock-$.01 par value, 175,000,000 shares
authorized, 58,356,546 and 58,870,291 shares
issued, respectively 584 589
Additional paid-in capital 83,493 87,957
Accumulated other comprehensive income 1,510 1,679
Retained earnings 70,225 85,477
Treasury stock, 8,247,119 shares at cost (62,190) (62,190)
Total stockholders' equity 93,622 113,512
Total liabilities and stockholders'
equity $115,064 $147,696
eResearchTechnology, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
Year Ended December 31,
Net income $8,310 $15,252
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 11,253 15,129
Cost of sales of equipment 3,722 1,143
Provision for uncollectible accounts 111 30
Share-based compensation 2,975 2,004
Investment impairment charge 226 -
Changes in operating assets and liabilities
exclusive of CCSS acquisition:
Accounts receivable (2,567) (4,192)
Prepaid expenses and other 132 352
Accounts payable 950 (2,147)
Accrued expenses (1,779) 2,806
Income taxes (2,104) 3,137
Deferred revenues (4,897) 2,487
Net cash provided by operating
activities 16,332 36,001
Purchases of property and equipment (15,181) (11,073)
Purchases of investments (46,425) (58,008)
Proceeds from sales of investments 40,658 91,555
Payments for acquisition - (35,800)
Net cash used in investing activities (20,948) (13,326)
Repayment of capital lease obligations (153) (2,504)
Proceeds from exercise of stock options 3,851 1,655
Stock option income tax benefit 3,400 760
Repurchase of common stock for treasury (5,803) -
Net cash provided by (used in) financing
activities 1,295 (89)
Effect of exchange rate changes on cash 386 (1)
Net (decrease) increase in cash and cash
equivalents (2,935) 22,585
Cash and cash equivalents, beginning of period 18,432 15,497
Cash and cash equivalents, end of period $15,497 $38,082
|SOURCE eResearchTechnology, Inc.|
Copyright©2008 PR Newswire.
All rights reserved